Harvard Apparatus Regenerative Technology Return on Equity

Harvard Apparatus Regenerative Technology (HRGN) currently reports a ROE of 484.63%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Harvard Apparatus Regenerative Technology's ROE history and peer comparisons.

Harvard Apparatus Regenerative Technology's ROE of 484.63% is higher than the Healthcare sector average of -75.59%. That is roughly 741.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Harvard Apparatus Regenerative Technology's current 484.63% should be judged against Healthcare norms (sector average: -75.59%) and against HRGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 484.63%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Harvard Apparatus Regenerative Technology, and consider following HRGN for alerts when major investors trade the stock.

Harvard Apparatus Regenerative Technology is classified in the Healthcare sector. On ROE, it currently shows 484.63% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HRGN with unrelated industries.